Charles Fournier

4.4k total citations
112 papers, 3.3k citations indexed

About

Charles Fournier is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Charles Fournier has authored 112 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 23 papers in Surgery and 22 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Charles Fournier's work include Head and Neck Cancer Studies (12 papers), Sarcoma Diagnosis and Treatment (11 papers) and Vascular Tumors and Angiosarcomas (10 papers). Charles Fournier is often cited by papers focused on Head and Neck Cancer Studies (12 papers), Sarcoma Diagnosis and Treatment (11 papers) and Vascular Tumors and Angiosarcomas (10 papers). Charles Fournier collaborates with scholars based in France, United States and Luxembourg. Charles Fournier's co-authors include Nicolas Penel, Jean‐Louis Lefebvre, Nicolás Isambert, D Guiban, Christine Chevreau, Emmanuelle Bompas, B Hecquet, S. Taïeb, Sonia Cerdas and B Guilhaume and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Charles Fournier

107 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Charles Fournier France 31 1.2k 1.0k 699 657 419 112 3.3k
Jan Paul de Boer Netherlands 35 1.6k 1.3× 788 0.8× 698 1.0× 359 0.5× 363 0.9× 118 3.9k
Olfred Hansen Denmark 37 1.1k 0.9× 1.9k 1.8× 1.0k 1.5× 220 0.3× 769 1.8× 174 4.6k
Tatsuo Uchida United States 34 322 0.3× 444 0.4× 863 1.2× 266 0.4× 529 1.3× 110 3.1k
Dexiang Gao United States 39 1.3k 1.0× 1.1k 1.0× 609 0.9× 276 0.4× 1.1k 2.6× 147 4.1k
Ji‐An Liang Taiwan 34 982 0.8× 1.1k 1.1× 935 1.3× 104 0.2× 617 1.5× 208 4.0k
Jennifer Turner Australia 38 1.2k 0.9× 822 0.8× 474 0.7× 505 0.8× 960 2.3× 144 4.8k
David Elashoff United States 32 1.0k 0.8× 564 0.5× 713 1.0× 165 0.3× 1.3k 3.1× 88 4.1k
Koji Tsuboi Japan 38 851 0.7× 1.6k 1.5× 547 0.8× 183 0.3× 576 1.4× 163 4.3k
David R. Doody United States 31 1.2k 1.0× 356 0.3× 615 0.9× 154 0.2× 1.1k 2.6× 85 3.4k
Donn C. Young United States 42 1.8k 1.5× 1.1k 1.1× 1.4k 2.0× 145 0.2× 1.2k 2.9× 137 5.7k

Countries citing papers authored by Charles Fournier

Since Specialization
Citations

This map shows the geographic impact of Charles Fournier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Fournier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Fournier more than expected).

Fields of papers citing papers by Charles Fournier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Fournier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Fournier. The network helps show where Charles Fournier may publish in the future.

Co-authorship network of co-authors of Charles Fournier

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Fournier. A scholar is included among the top collaborators of Charles Fournier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Fournier. Charles Fournier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Fournier, Charles, et al.. (2023). Sainte-Soline, le retour des luttes écologiques en France. N° 54(1). 20–28.
3.
Fournier, Charles, Véronique Christophe, M. Reich, et al.. (2015). Selection of ultimately ill cancer patients able to fulfill a questionnaire: Identification of inherent biases. Bulletin du Cancer. 102(9). 730–736. 1 indexed citations
4.
Narducci, Fabrice, et al.. (2014). Single-Port Access Laparoscopic Surgery in Gynecologic Oncology. International Journal of Gynecological Cancer. 24(6). 1126–1132. 10 indexed citations
5.
Penel, Nicolas, Isabelle Ray‐Coquard, Christine Bal-Mahieu, et al.. (2013). Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. Targeted Oncology. 9(3). 273–277. 19 indexed citations
6.
Adenis, Antoine, Isabelle Ray‐Coquard, Antoîne Italiano, et al.. (2013). A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours. British Journal of Cancer. 109(10). 2574–2578. 21 indexed citations
7.
Ray‐Coquard, Isabelle, Antoîne Italiano, Emmanuelle Bompas, et al.. (2012). Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO). The Oncologist. 17(2). 260–266. 148 indexed citations
8.
Taïeb, S., N. Rocourt, Fabrice Narducci, et al.. (2011). Inefficacité du dépistage des cancers tubo-ovariens dans les situations de risque héréditaire de cancer de l’ovaire ; l’expérience du Centre Oscar-Lambret. Bulletin du Cancer. 98(2). 113–119. 3 indexed citations
9.
Kolesnikov-Gauthier, H., Laurence Vanlemmens, Marie‐Christine Baranzelli, et al.. (2011). Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG–PET after the first course. Breast Cancer Research and Treatment. 131(2). 517–525. 38 indexed citations
10.
Penel, Nicolas, Charles Fournier, & J. Bérille. (2010). Proposal for size justification of expanded cohort at phase-2-recommended dose. Investigational New Drugs. 29(4). 713–715. 5 indexed citations
11.
Hebbar, Mohamed, Frédéric Di Fiore, Thierry Conroy, et al.. (2007). Assessment of Baseline Clinical Predictive Factors of Response to Cetuximab-Irinotecan in Patients with Irinotecan-Refractory Metastatic Colorectal Cancer. Oncology. 73(3-4). 185–191. 8 indexed citations
12.
13.
Palau, R., F. Mal, Christos Christidis, et al.. (2003). Transient elastrography a new non invasive method for assessment of liver fibrosis: Results in patients with HCV chronic hepatitis. Journal of Hepatology. 38. 126–126. 1 indexed citations
14.
Fournier, Charles, et al.. (2002). Dosimétrie in vivo et radiothérapie des cancers du sein. Cancer/Radiothérapie. 6(5). 296–299. 1 indexed citations
15.
Hebbar, Mohamed, et al.. (1999). Prognostic value of circulating soluble E-selectin concentrations in node-negative breast cancer patients.. PubMed. 5(6). 1427–33. 25 indexed citations
16.
Comoy, Emmanuel, Joël Pestel, Catherine Duez, et al.. (1998). The House Dust Mite Allergen, Dermatophagoides pteronyssinus , Promotes Type 2 Responses by Modulating the Balance Between IL-4 and IFN-γ. The Journal of Immunology. 160(5). 2456–2462. 76 indexed citations
17.
Comoy, Emmanuel, Joël Pestel, Catherine Duez, et al.. (1998). The house dust mite allergen, Dermatophagoides pteronyssinus, promotes type 2 responses by modulating the balance between IL-4 and IFN-gamma.. PubMed. 160(5). 2456–62. 98 indexed citations
18.
Boughattas, Naceur A., B Hecquet, Charles Fournier, et al.. (1994). Comparative pharmacokinetics of oxaliplatin (L‐OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time. Biopharmaceutics & Drug Disposition. 15(9). 761–773. 29 indexed citations
19.
Boughattas, Naceur A., Françis Lévi, B Hecquet, et al.. (1988). Circadian time dependence of murine tolerance for carboplatin. Toxicology and Applied Pharmacology. 96(2). 233–247. 31 indexed citations
20.
Vennin, Philippe, et al.. (1985). Sequential measurement of intratumoral platinum concentration in cervix uterine tumors after cis-dichlorodiammineplatinum (CDDP) administration.. PubMed. 5(4). 369–70. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jan Paul de Boer Breakdown of academic impact, for papers by Olfred Hansen Breakdown of academic impact, for papers by Tatsuo Uchida Breakdown of academic impact, for papers by Dexiang Gao Breakdown of academic impact, for papers by Ji‐An Liang Breakdown of academic impact, for papers by Jennifer Turner Breakdown of academic impact, for papers by David Elashoff Breakdown of academic impact, for papers by Koji Tsuboi Breakdown of academic impact, for papers by David R. Doody Breakdown of academic impact, for papers by Donn C. Young
Rankless by CCL
2026